지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2020.10
- 수록면
- 320 - 324 (5page)
- DOI
- https://doi.org/10.3904/kjm.2020.95.5.320
이용수
초록· 키워드
오류제보하기
Standard post-remission therapy for adult patients with high-risk acute lymphoblastic leukemia (ALL) is allogeneic hematopoietic cell transplantation (allo-HCT). However, 20?30% of patients treated with allo-HCT subsequently relapse, and their long-term survival outcomes are very poor even after the next allo-HCT. The poor survival outcomes reported by previous studies have mainly been due to low complete remission (CR) rates and high mortality from conventional salvage chemo-regimens, such as mitoxantrone plus etoposide plus cytarabine (MEC) or fludarabine plus cytarabine plus idarubicin (FLA-Ida). However, several novel agents with proven high remission rates and a good measurable residual disease response can now be administered. The representative novel agents recently introduced are blinatumomab (anti-CD19 bispecific T-cell engager) and inotuzumab ozogamicin (anti-CD22 antibody- calicheamicin conjugate). In South Korea, blinatumomab has been used since October 2016 and inotuzumab ozogamicin has been in use since October 2019 under coverage by the national insurance system. Studies on blinatumomab in Korea showed that this drug is effective when used as an early salvage line, even in patients who relapse after an initial allo-HCT. However, a previous study revealed that relapsed patients with a short CR duration of < 12 months post-HCT show a poor response to blinatumomab compared to patients with a longer CR duration. Also, some early relapsed cases with active acute graft-versus-host disease (GVHD) show aggravated GVHD with the use of blinatumomab. No real-world data are available in Korea for inotuzumab, but previous trials have reported a good CR and proceeding rates to allo-HCT comparable to blinatumomab. We have experienced hepatotoxicity including venoocclusive disease in post-HCT relapsed patients treated with inotuzumab.
목차
등록된 정보가 없습니다.
참고문헌 (19)
참고문헌 신청
Jabbour E / 2017 / Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia / Cancer 123:294~302
O'Brien S / 2008 / Outcome of adults with acute lymphocytic leukemia after second salvage therapy / Cancer 113:3186~3191
Gökbuget N / 2012 / Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation / Blood 120:2032~2041
McCloskey JK / 2019 / Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias / Blood 134(Suppl 1):3812
Jabbour E / 2018 / Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage / Cancer 124:4044~4055
O'Brien S / 2008 / Outcome of adults with acute lymphocytic leukemia after second salvage therapy / Cancer 113:3186~3191
Gökbuget N / 2012 / Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation / Blood 120:2032~2041
McCloskey JK / 2019 / Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias / Blood 134(Suppl 1):3812
Jabbour E / 2018 / Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage / Cancer 124:4044~4055
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Treatment and clinical outcomes of patients relapsing after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome
Blood Research
2018 .01
-
Blinatumomab as a Curative Therapy Option for Relapsed/Refractory Infant Acute Lymphoblastic Leukemia Post-Hematopoietic Stem Cell Transplantation - Case Report
Clinical Pediatric Hematology-Oncology
2024 .04
-
Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk
Blood Research
2022 .06
-
Outcome of Intensive Therapy for Children with Relapsed Acute Myeloid Leukemia: A Single Institution Korean Study
Cancer Research and Treatment
2022 .10
-
Prognostic factors and treatment of pediatric acute lymphoblastic leukemia
Clinical and Experimental Pediatrics
2017 .01
-
Outcome and prognostic factors of children with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib followed by allogeneic hematopoietic cell transplantation in first remission
Blood Research
2019 .01
-
Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
Yonsei Medical Journal
2020 .01
-
재발성/불응성 소아 급성림프모구백혈병 환자의 치료 경향 및 성적에 대한 다기관 후향적 관찰 연구
Clinical Pediatric Hematology-Oncology
2017 .01
-
Isolated Breast Relapse of Early T-Cell Precursor Acute Lymphoblastic Leukemia after Stem Cell Transplantation: A Pediatric Case and Literature Review
Clinical Pediatric Hematology-Oncology
2022 .04
-
Therapy-related acute myeloid leukemia in a patient with B-cell acute lymphoblastic leukemia
Blood Research
2021 .12
-
Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study
Journal of Korean Medical Science
2017 .01
-
A Case of Pediatric Precursor B-cell Acute Lymphoblastic Leukemia Associated with Translocations (14;18)(q32;q21) and (8;9)(q24;p13)
Clinical Pediatric Hematology-Oncology
2017 .01
-
Treatment Outcomes in Children and Adolescents with Relapsed or Progressed Solid Tumors: a 20-year, Single-Center Study
Journal of Korean Medical Science
2018 .01
-
Rapid resolution of bone marrow necrosis mimicking relapse of pediatric acute lymphoblastic leukemia
Blood Research
2020 .01
-
Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: recent advances and controversies
Blood Research
2015 .01
-
Treatment and response of autoimmune cytopenia occurring after allogeneic hematopoietic cell transplantation in children
Blood Research
2017 .01
-
Outcomes of Anti-CD19 CAR-T Treatment of Pediatric B-ALL with Bone Marrow and Extramedullary Relapse
Cancer Research and Treatment
2022 .07
-
Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study
Gut and Liver
2021 .09
-
Outcomes of limited period of adalimumab treatment in moderate to severe Crohn’s disease patients: Taiwan Society of Inflammatory Bowel Disease Study
Intestinal research
2017 .01
-
An Elevated Platelet Count Increases the Risk of Relapse in Ulcerative Colitis Patients with Mucosal Healing
Gut and Liver
2018 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0